Exclusive Online Content
atai Life Sciences Initiates Phase 2b Proof-of-Concept Trial of RL-007 for Cognitive Impairment Associated With Schizophrenia
The Phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)…..
Carrick Therapeutics & The Menarini Group Announce Clinical Trial Collaboration
Carrick Therapeutics and the Menarini Group recently announced a clinical trial collaboration and supply agreement that covers the execution of a Phase 2 clinical trial to evaluate the novel combination of….
Paratek Pharmaceuticals Announces Positive Top Line Data From Pilot Efficacy Study for the Treatment of Pulmonary Anthrax & Acceptance of the Second Procurement of NUZYRA Under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. recently announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate….
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination With Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Adagene Inc. recently announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of….
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial & Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, a Novel, Oral Therapeutic for the Prevention of Lyme Disease
Tarsus Pharmaceuticals, Inc. recently announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial…..
MoonLake Immunotherapeutics Screens First Patient in Phase 2 Study of the Nanobody Sonelokimab in Active Psoriatic Arthritis
MoonLake Immunotherapeutics AG recently announced the first subject has been screened in the US in a Phase 2 clinical study of the Nanobody sonelokimab in patients with….
Hovione & GEA announce a Strategic Collaboration to Advance Continuous Tableting
Hovione & GEA recently announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years….
Syneos Health Extends Partnership With Medable; Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient
Syneos Health recently announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of….
Sosei Heptares Receives $10-Million Milestone Payment in Discovery Collaboration With AbbVie Targeting Inflammatory Diseases
Sosei Group Corporation recently announced it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune….
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
Lantheus Holdings, Inc. recently announced a strategic collaboration with SonoThera, Inc. in which Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene…
EXCLUSIVE ONLINE CONTENT
Abzena Launches Next-Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics & Bioconjugates
Abzena recently announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein….
Biolojic Design Announces Nektar Therapeutics Has Exercised its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021….
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….